Form 8-K - Current report:
SEC Accession No. 0001641172-25-006428
Filing Date
2025-04-28
Accepted
2025-04-28 16:15:16
Documents
22
Period of Report
2025-04-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 60785
2 ex1-1.htm EX-1.1 468741
3 ex4-1.htm EX-4.1 123700
4 ex4-2.htm EX-4.2 111157
5 ex4-3.htm EX-4.3 115081
6 ex10-1.htm EX-10.1 229239
7 ex99-1.htm EX-99.1 11262
8 ex99-2.htm EX-99.2 12536
9 GRAPHIC ex99-2_001.jpg GRAPHIC 4496
  Complete submission text file 0001641172-25-006428.txt   1600569

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE bctx-20250424.xsd EX-101.SCH 3989
11 XBRL DEFINITION FILE bctx-20250424_def.xml EX-101.DEF 27025
12 XBRL LABEL FILE bctx-20250424_lab.xml EX-101.LAB 37320
13 XBRL PRESENTATION FILE bctx-20250424_pre.xml EX-101.PRE 25645
24 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6852
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 25880544
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)